Patents by Inventor Per Holm

Per Holm has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220218627
    Abstract: Provided is a method of treating patients with Cluster Headache (CH) including chronic Cluster Headache (cCH) comprising intranasal administration to a patient in need thereof of an aqueous composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine, which may reduce or eliminate side effects of ketamine when used in the treatment of Cluster Headache, and to a composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine for use in the treatment of Cluster Headache, wherein the composition is in a nasal dosage form such as a nasal spray.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 14, 2022
    Inventors: Per Holm, Ole Pedersen, John Claude Krusz
  • Publication number: 20220193046
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Application
    Filed: August 4, 2021
    Publication date: June 23, 2022
    Inventors: Robert D Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 11185871
    Abstract: The present invention relates to an electrostatic precipitator (ESP) system (1) for removal of particles from a flue gas flowing in a flow passage (4) being delimited by a primary collection in the form of a collection plate (5). The system comprises a discharge electrode (11) arranged in the flow passage and connected to a high voltage generator (12) providing for an electric field around the discharge electrode. The system further has a secondary collection electrode in the form of a grid (101) arranged within the collection plate and made of an electrically conductive material. The presence of such a grid improves the efficiency of the precipitator. In some embodiments, the ESP system comprises an actuator (112) for moving the grid upwards and letting it drop onto an internal bottom structure (109). The movement between the collection plate and the grid as well as the impact force imparted to the dropping grid both result in a removal of collected particles.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: November 30, 2021
    Assignee: exodraft A/S
    Inventors: Peter Hermansen, Seyednezamaddin Azizaddini, Per Holm Hansen
  • Patent number: 11129815
    Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: September 28, 2021
    Assignee: VELOXIS PHARMACEUTICALS INC.
    Inventor: Per Holm
  • Patent number: 11123331
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 21, 2021
    Assignee: VELOXIS PHARMACEUTICALS, INC.
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 11110081
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: September 7, 2021
    Assignee: VELOXIS PHARMACEUTICALS, INC.
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Patent number: 11077096
    Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: August 3, 2021
    Assignee: VELOXIS PHARMACEUTICALS INC.
    Inventors: Per Holm, Tomas Norling
  • Publication number: 20210046055
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Inventors: Robert D. GORDON, Per HOLM, Anne-Marie LADEMANN, Tomas NORLING
  • Publication number: 20210046054
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Inventors: Robert D. GORDON, Per HOLM, Anne-Marie LADEMANN, Tomas NORLING
  • Patent number: 10864199
    Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: December 15, 2020
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
  • Publication number: 20200289478
    Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
    Type: Application
    Filed: October 18, 2019
    Publication date: September 17, 2020
    Inventor: Per Holm
  • Patent number: 10661354
    Abstract: Holder for a rotary tool which holder is formed with a holder body comprising a rear drive end and a front connection end having a connection thread for the connection of the tool. The holder comprises a thrust collar having a flat contact surface facing a connection end of the holder. The holder comprises an axially movable operating means, a number of restraint elements placed in one or more spaces in the holder body which restraint elements in a first axial position of the operating means are prevented from radial movement in said spaces and which restraint elements in a second axial position of the operating means allow radial movement in said spaces. Each one of said spaces for the restraint elements is limited in the axial direction by a front limiting wall and a rear limiting wall, which two limiting walls are parts of the holder body.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: May 26, 2020
    Assignee: KAPMAN AB
    Inventors: Erik Grindlund, Per Holm, Tomas Ivner, Nils Classon
  • Patent number: 10548880
    Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 4, 2020
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventor: Per Holm
  • Publication number: 20190282504
    Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.
    Type: Application
    Filed: November 13, 2018
    Publication date: September 19, 2019
    Inventors: Nikolaj Skak, Per Holm
  • Publication number: 20190168236
    Abstract: The present invention relates to an electrostatic precipitator (ESP) system (1) for removal of particles from a flue gas flowing in a flow passage (4) being delimited by a primary collection in the form of a collection plate (5). The system comprises a discharge electrode (11) arranged in the flow passage and connected to a high voltage generator (12) providing for an electric field around the discharge electrode. The system further has a secondary collection electrode in the form of a grid (101) arranged within the collection plate and made of an electrically conductive material. The presence of such a grid improves the efficiency of the precipitator. In some embodiments, the ESP system comprises an actuator (112) for moving the grid upwards and letting it drop onto an internal bottom structure (109). The movement between the collection plate and the grid as well as the impact force imparted to the dropping grid both result in a removal of collected particles.
    Type: Application
    Filed: December 3, 2018
    Publication date: June 6, 2019
    Inventors: Peter Hermansen, Seyednezamaddin Azizaddini, Per Holm Hansen
  • Publication number: 20190134716
    Abstract: Holder for a rotary tool which holder is formed with a holder body comprising a rear drive end and a front connection end having a connection thread for the connection of the tool. The holder comprises a thrust collar having a flat contact surface facing a connection end of the holder. The holder comprises an axially movable operating means, a number of restraint elements placed in one or more spaces in the holder body which restraint elements in a first axial position of the operating means are prevented from radial movement in said spaces and which restraint elements in a second axial position of the operating means allow radial movement in said spaces. Each one of said spaces for the restraint elements is limited in the axial direction by a front limiting wall and a rear limiting wall, which two limiting walls are parts of the holder body.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Applicant: Kapman AB
    Inventors: Erik GRINDLUND, Per HOLM, Tomas IVNER, Nils CLASSON
  • Patent number: 10166190
    Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: January 1, 2019
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventors: Nikolaj Skak, Per Holm
  • Publication number: 20180228779
    Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.
    Type: Application
    Filed: August 15, 2017
    Publication date: August 16, 2018
    Inventors: Per Holm, Tomas Norling
  • Publication number: 20180214422
    Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
    Type: Application
    Filed: August 14, 2017
    Publication date: August 2, 2018
    Inventor: Per Holm
  • Patent number: 9763920
    Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: September 19, 2017
    Assignee: VELOXIS PHARMACEUTICALS A/S
    Inventor: Per Holm